IRVINE, Calif., March 04, 2025--(BUSINESS WIRE)--Immunis, Inc., a clinical-stage biotech developing multi-active biologics for age and disease-related immune dysregulation, announces that it has ...
IRVINE, Calif.--(BUSINESS WIRE)--Immunis, Inc., a clinical-stage biotech developing multi-active biologics for age and disease-related immune dysregulation, announces that it has initiated ...
Immunis, Inc., a clinical-stage biotech developing multi-active biologics for age and disease-related immune dysregulation, announces that it has initiated treatment in several patients of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback